Thompson Siegel & Walmsley LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Thompson Siegel & Walmsley LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 76,284 shares of the medical equipment provider's stock, valued at approximately $8,372,000. Thompson Siegel & Walmsley LLC owned 0.11% of Lantheus at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of Lantheus in the third quarter worth about $435,000. Intech Investment Management LLC raised its position in Lantheus by 219.4% during the third quarter. Intech Investment Management LLC now owns 49,131 shares of the medical equipment provider's stock valued at $5,392,000 after acquiring an additional 33,747 shares in the last quarter. Jennison Associates LLC acquired a new position in Lantheus in the third quarter valued at approximately $980,000. Premier Fund Managers Ltd purchased a new stake in Lantheus in the 3rd quarter worth approximately $693,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Lantheus by 16.6% during the 3rd quarter. PNC Financial Services Group Inc. now owns 9,021 shares of the medical equipment provider's stock worth $990,000 after purchasing an additional 1,286 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LNTH. JMP Securities dropped their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Truist Financial restated a "buy" rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Stock Performance

Shares of LNTH traded up $3.20 during mid-day trading on Friday, reaching $90.52. 2,014,903 shares of the company's stock traded hands, compared to its average volume of 1,020,692. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The stock has a market capitalization of $6.29 billion, a P/E ratio of 14.97 and a beta of 0.51. The business's 50-day moving average price is $103.43 and its 200-day moving average price is $96.53.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.